Ian Tannock on Common Sense Oncology principles for phase 3 randomised clinical trials

The Lancet Oncology in conversation with
03/02/2025 18 min
Ian Tannock on Common Sense Oncology principles for phase 3 randomised clinical trials

Listen "Ian Tannock on Common Sense Oncology principles for phase 3 randomised clinical trials"

Descargar episodio

Episode Synopsis

Professor Ian Tannock (Princess Margaret Cancer Centre and the University of Toronto, Toronto, Canada) discusses his Policy Review on Common Sense Oncology principles for the design, analysis and reporting of phase 3 randomised clinical trials.Tell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

More episodes of the podcast The Lancet Oncology in conversation with

Andre Pfob and Peter Dubsky on The Lucerne Toolbox 3 25/11/2025
Gary Rodin on The human crisis in cancer: a Lancet Oncology Commission 02/11/2025
Matthias Preusser on the phase 2 TUXEDO-3 trial 27/10/2025
Andrea Necchi on TAR-200 plus cetrelimab as neoadjuvant therapy in patients with muscle-invasive bladder cancer 29/09/2025
Linda Bi, Ruchit Patel, Chloe Gui, Farshad Nassiri, and Matija Snuderl on TERT expression and TERT promoter mutations in meningiomas 02/09/2025
Jinming Li on patterns in genomic mutations among patients with early-onset colorectal cancer 28/07/2025
Abdalla Awidi on cancer control in the Middle East 11/06/2025
ASCO 2025 Debrief 11/06/2025
Caroline Robert on treatments for patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN trial) 28/05/2025
Richard Bryant on transperineal vs transrectal biopsy for prostate cancer 30/04/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA